Financial Performance - Total operating revenue for Q1 2019 was CNY 156,308,732.68, an increase of 18.64% compared to CNY 131,749,849.30 in the same period last year[7]. - Net profit attributable to shareholders was CNY 29,854,699.68, representing a growth of 25.74% from CNY 23,743,408.83 year-on-year[7]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 26,295,585.08, up 29.11% from CNY 20,367,165.19 in the previous year[7]. - Basic earnings per share increased to CNY 0.290, a rise of 26.09% compared to CNY 0.230 in the same quarter last year[7]. - Net profit for Q1 2019 reached CNY 29,274,813.57, representing a 27% increase from CNY 23,089,374.69 in Q1 2018[39]. - The total comprehensive income for Q1 2019 was CNY 15,239,132.08, which is the same as the net profit due to no other comprehensive income items reported[44]. Cash Flow - The net cash flow from operating activities was CNY 18,232,746.92, down 30.84% from CNY 26,363,112.43 in the previous year[7]. - Cash flow from operating activities generated a net amount of CNY 18,232,746.92, compared to CNY 26,363,112.43 in the previous year, indicating a decrease of 30.8%[47]. - Cash flow from investment activities showed a net outflow of CNY 27,653,949.36, compared to a net outflow of CNY 260,959,551.45 in the previous year[48]. - The company’s cash flow from financing activities was CNY 100,000.00, a significant decrease from CNY 6,000,000.00 in Q1 2018[48]. - The net cash increase for the first quarter was -30,822,903.14 CNY, compared to -233,309,068.97 CNY in the same period last year[52]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,170,514,974.46, reflecting a slight increase of 0.70% from CNY 2,155,356,658.35 at the end of the previous year[7]. - The company's current assets totaled CNY 1,555,895,480.43, compared to CNY 1,545,642,739.65 at the end of 2018, indicating a slight increase[28]. - Total liabilities decreased to CNY 436,259,964.04 from CNY 445,771,822.49 at the end of 2018[30]. - Total liabilities decreased to CNY 377,849,361.28 from CNY 397,501,955.62, indicating a reduction of approximately 4.3%[35]. - The total equity attributable to shareholders was 1,699,551,638.99 CNY, with total equity amounting to 1,709,584,835.86 CNY[55]. Operating Costs and Expenses - Operating costs surged by 161.10% to ¥18,691,841.87, mainly due to the consolidation of subsidiary financial statements[15]. - The company incurred operating expenses of CNY 152,574,647.79 in Q1 2019, compared to CNY 141,858,188.25 in Q1 2018, reflecting an increase of 7.5%[47]. - The company reported a significant increase in R&D expenses, totaling CNY 10,996,448.47 for Q1 2019, with no comparable figure from the previous year[37]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,612[11]. - The company's equity attributable to shareholders rose to CNY 1,722,127,981.19 from CNY 1,699,551,638.99 at the end of 2018[31]. Non-Recurring Items - The company reported non-recurring gains and losses totaling CNY 3,559,114.60 for the reporting period[9]. - The company has not reported any non-compliance with external guarantees during the reporting period[23]. - There were no significant changes in net profit or losses compared to the previous year[23]. - The company has not utilized any idle raised funds for temporary working capital during the reporting period[28]. Future Plans - The company plans to enhance market development and academic promotion activities for its main product, Jinlujie, in response to market challenges[16]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[39].
海特生物(300683) - 2019 Q1 - 季度财报